BioSpace News Archive

Surging cases of sexually transmitted disease is spurring researchers to verify and reintroduce new innovations for the treatment

Increasing preference for non-invasive surgical procedures will remain a key factor driving product development and commercialization in the operating room equipment market for the foreseeable future.

The demand for blood purification therapy has witnessed considerable growth over the last couple of decades and is increasingly being used to treat a range of disorders, which cannot be treated by conventional therapies, including surgery and drug administration.

TMR’s report on the global heel incision devices market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030.

Synthetic cannabinoid was primarily conceptualized as a critical pharmacological tool to evaluate the endocannabinoid system.

The global viral vector and plasmid DNA testing services market is estimated to be influenced by the increased innovation and spending in research and development activities relating to the field.

Rapid Micro Biosystems, Inc., the leading provider of data integrity and automation technology for microbial detection in biopharmaceutical manufacturing, today announced the completion of an $81 million equity financing.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announces its financial results for the first quarter ended January 31, 2021 and provides a business update.

MannKind Corporation announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 pursuant to the exercise in full of the initial purchasers’ option in connection with MannKind’s previously-announced private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent and new data covering what the Company believes to be the first gene-modified, stem cell derived, universal donor dendritic cell cancer immunotherapy.